Array BioPharma News

The Dow Jones Industrial Average finished the trading day at 12,890.46, up 6.51 points .

BOULDER, Colo. -- -- Array BioPharma Inc. today announced that its President and Chief Scientific Officer, Kevin Koch, will speak at the Leerink Swann Healthcare Conference in New York.

Shares of the following companies had unusual moves in U.S. trading. Stock symbols are in parentheses and prices are as of 4 p.m. in New York.

The top after-market NASDAQ Losers Wednesday were: Diamond Foods, iRobot Corp, Groupon, Array BioPharma, TripAdvisor, Celldex Therapeutics, TriQuint Semiconductor, Neurocrine Biosciences, Perceptron and Affymetrix.

Boulder-based Array BioPharma today made a shelf registration filing with the Securities and Exchange Commission indicating it plans to sell shares of its common stock in an underwritten public offering.

The stock last traded at $2.71, up from its previous close of $2.40. Separately, analysts at Jefferies Group reiterated a "buy" rating on shares of Array Biopharma Incorporated in a research note to investors on Monday, December 12nd.

Array BioPharma Inc. announced that it has elected Gwen A. Fyfe, M.D., to its Board of Directors.

Array reported revenue of $23.2 million for the second quarter of fiscal 2012, compared to revenue of $16.5 million for the same period in fiscal 2011.

Array BioPharma Inc. will report financial results for the second quarter of fiscal 2012 on Monday, January 30, 2012, and will hold a conference call on Tuesday, January 31, 2012 at 9:00 a.m. eastern time to discuss these results.

Array BioPharma Inc. today announced that Robert E. Conway has resigned as Chief Executive Officer and a Director for personal reasons.

The NASDAQ closed at 2710.67, down 14.03 or 0.51%. Markets are closed Monday, January 16th.

January 13, 2012, Comprehensive Care Corp. announced today that they have finished the build out of a fully contracted and credentialed specialty behavioral health provider network across the island of Puerto Rico.

The stock last traded at $2.32, up from its previous close of $2.13. Separately, analysts at Jefferies Group reiterated a "buy" rating on shares of Array Biopharma Incorporated in a research note to investors on Monday, December 12nd.